– USA, MA – Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointments of Dr Fouad Namouni, M.D. and Dr Richard Peters, M.D., Ph.D. to its Board of Directors.
“Both Drs. Namouni and Peters are distinguished industry leaders with years of experience in advancing important new therapeutics to patients in need,” said President and CEO, Christian Schade. “Their advice and counsel will be invaluable as Aprea continues with its progress to advance our mutant p53 reactivator oncology programs. We are thrilled to welcome Fouad and Richard to the Aprea team and our Board of Directors.”
In addition, Guido Magni, M.D., Ph.D. will step down from the Company’s Board of Directors, effective June 30, 2020.
Christian Schade added: Finally, on behalf of the Board of Directors and all Aprea employees, we are grateful to Guido Magni for his years of strategic insight and guidance throughout his tenure on Aprea’s Board.”
About Dr Fouad Namouni
Fouad Namouni, M.D., brings more than 20 years of oncology and immuno-oncology drug development expertise, most recently serving as SVP & Head of Oncology Development at Bristol-Myers Squibb, with responsibility for driving product development plans from early-stage clinical development through commercialization. Prior to serving as Head of Oncology Development, Dr. Namouni was Head of Medical Affairs at BMS and prior to that position, he was Head of Development for Opdivo and Yervoy, immunotherapy medications used in the treatment of cancer.
Dr. Namouni holds an M.D. degree from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.
About Dr Richard Peters
Richard Peters, M.D., Ph.D., brings more than 25 years of experience developing new therapies for difficult-to-treat diseases. He currently serves as President, CEO and Director at Yumanity Therapeutics Inc. Dr. Peters joined Yumanity from Merrimack Pharmaceuticals, Inc. where he was President & CEO. Prior to Merrimack, he served as SVP and Head, Global Rare Diseases at Genzyme (Sanofi).
Dr. Peters is a Harvard-trained physician and scientist, has served on the faculty at the Massachusetts General Hospital, and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School. Dr. Peters holds M.D. and Ph.D. degrees from the Medical University of South Carolina.
About Aprea Therapeutics
Aprea Therapeutics Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p53. The Company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia.
For more information: https://www.aprea.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.